| Document |
Document Title |
|
WO/2020/027586A1 |
The present invention relates to a composition for accelerating muscle differentiation, comprising gallic acid as an active ingredient, wherein the active ingredient of the present invention, gallic acid, has the effects of increasing ce...
|
|
WO/2020/025986A1 |
The present invention relates to stable injectable solutions comprising diclofenac sodium and thiocolchicoside as active ingredients and a liquid carrier comprising propylene glycol, benzyl alcohol and a polydentate ligand. The solutions...
|
|
WO/2020/024247A1 |
Biologic preparation for relieving pain in neck, shoulder, waist, and leg and having function of strengthening the muscles and vessels, comprising an agent for promoting blood circulation and removing obstruction in channels, a joint bio...
|
|
WO/2020/028836A1 |
Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on m...
|
|
WO/2020/028832A1 |
Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on m...
|
|
WO/2020/026167A1 |
The present invention provides C1orf54 polypeptides and variants thereof with myokine activity as well as compositions and methods for treating, ameliorating or preventing muscle-related disorders.
|
|
WO/2019/036471A9 |
Disclosed are compositions comprising branched chain amino acids, urea cycle amino acids and essential amino acids for use in treating or preventing liver diseases and disorders with hyperammonemia or muscle wasting in a subject.
|
|
WO/2020/022518A1 |
This prophylactic agent and/or therapeutic agent for neurological disorders including amyotrophic lateral sclerosis comprises necdin as an effective component. The prophylactic agent and/or therapeutic agent may be: necdin or a variant t...
|
|
WO/2020/023918A1 |
Provided are therapies, including standalone and combination therapies, for treating neuropilin-2 (NRP2)-associated diseases and conditions, which include the use of at least one histidyl-tRNA synthetase (HRS) polypeptide.
|
|
WO/2020/020231A1 |
Disclosed are a two-quaternary ammonium compound and a preparation method and a use thereof. Specifically, a two-quaternary ammonium compound depicted by formula (I) is provided: wherein L1 is a C1 to C8 alkylene group; L2 is a C1 to C8 ...
|
|
WO/2020/020857A1 |
The present invention refers to exosomes obtained from fibro-adipogenic progenitors (FAPs) previously exposed to histone deacetylase (HDAC) inhibitors. It also relatesto such exosomes for the use in the treatment of muscular dystrophies,...
|
|
WO/2020/020230A1 |
Provided are a dication compound, a preparation method therefor and use thereof, and specifically discloses a dication compound represented by formula (I), stereoisomers having the structure of formula (I) or a mixture of the stereoisome...
|
|
WO/2020/017587A1 |
Provided are: a pyridazinone derivative and/or a pharmaceutically acceptable salt thereof, which is useful as a therapeutic agent and/or a prophylactic agent for diseases in which Nav1.1 is involved and various central nervous system dis...
|
|
WO/2020/016425A1 |
The present invention relates to a substance that activates the GDF5 pathway, for use in a method for the treatment of age-related sarcopenia or disuse atrophy.
|
|
WO/2020/017921A1 |
According to an embodiment of the present invention, provided are a pharmaceutical composition, for preventing or treating sarcopenia, containing a Salicornia europaea extract as an active ingredient, and a food composition, for preventi...
|
|
WO/2020/017913A1 |
Provided according to one embodiment of the present invention are a pharmaceutical composition for preventing or treating sarcopenia, comprising a myokine as an active ingredient, and a food composition for preventing or alleviating sarc...
|
|
WO/2020/017915A1 |
Provided according to an embodiment of the present invention are a pharmaceutical composition comprising a phytoncide as an effective ingredient for preventing or treating sarcopenia and a food composition comprising a phytocide as an ef...
|
|
WO/2020/015659A1 |
Provided is a method for refining crude rocuronium bromide; the method comprises: using vacuum microwave drying or fluidized drying to remove residual solvent in crude rocuronium such that same meets medicinal requirements. Using the met...
|
|
WO/2020/014395A1 |
Disclosed herein are chimeric recombinant adeno-associated virus (rAAV) capsid proteins comprising a region of VP1μ that is replaced by the corresponding amino acids of the VP1μ of AAV serotype 1 (AAV1) or AAV serotype 8 (AAV8), and pa...
|
|
WO/2020/013108A1 |
To provide a drug for enabling the treatment or prevention of diseases which are caused by mitochondrial dysfunction and called mitochondrial diseases. In particular, to search for a function effect on mitochondrial diseases, said functi...
|
|
WO/2020/012003A1 |
The invention relates to compound of formula (I): in particular flavonoid derivatives (quercetin and catechin derivatives), for use in the prevention and/or the treatment of a disease or disorder involving both carbonyl and oxidative str...
|
|
WO/2020/014073A1 |
A characteristic of edible oil may be evaluated using a spectrometer. For example, optical reflectance data may be obtained from edible oil in situ in a frying apparatus housing the edible oil, the reflectance data corresponding to a spe...
|
|
WO/2020/013759A1 |
A process for preparing sugammadex sodium comprising: reacting a γ-cyclodextrin of formula (I) with triphosgene in the presence of N-methyl-2-pyrrolidone to provide a compound of formula (II); and reacting the compound of formula (II) w...
|
|
WO/2020/013090A1 |
The present invention addresses the main problem of providing: a method for producing neuron-like cells from somatic cells without artificial gene transfection; neuron-like cells obtained by said production method; or a composition compr...
|
|
WO/2020/012480A1 |
Described herein are compositions for topical use comprising active agents to provide pain relief. The compositions comprise a magnesium salt, a cannabinoid and at least one additional topical analgesic agent. Additionally described here...
|
|
WO/2020/014072A1 |
The present invention describes the use of a NK1-antagonist, in constant combination with neostigmine, to facilitate the treatment of a patient suffering from myasthenia gravis by providing a therapeutically effective neostigmine bromide...
|
|
WO/2020/013397A1 |
The present invention relates to a composition for preventing and treating muscular diseases, enhancing muscular function or enhancing motor ability, having as an active ingredient hydrangenol or a Hydrangea extract containing same. Acco...
|
|
WO/2020/013307A1 |
Provided is, inter alia, a method for producing a concentrated yogurt for promoting muscle synthesis. A method for producing a concentrated yogurt, in which a yogurt is concentrated, is used to obtain a yogurt by fermenting a prepared yo...
|
|
WO/2020/009147A1 |
[Problem] To provide a stem cell filtrate formulation which is useful for hair regeneration, the alleviation of pain caused by interosseous joint disease such as osteoarthrosis and articular rheumatism, and the treatment of said disease,...
|
|
WO/2020/009444A1 |
The present invention relates to a gene and cell therapy product using a cell fusion technology and a use thereof. More particularly, cells which overexpress hemagglutinin neuraminidase (HN) and F (fusion) protein were found to have an i...
|
|
WO/2020/004594A1 |
This prophylactic or therapeutic agent for spinal muscular atrophy includes a compound represented by formula (I) or a salt thereof (in the formula: W1, W2, and W3 are each independently selected from the group consisting of C-R2, C-R3, ...
|
|
WO/2020/004675A1 |
The present invention relates to a composition containing an antisense oligonucleotide and a use thereof for the treatment of Duchenne muscular dystrophy. The present invention, specifically, relates to the composition effective for the ...
|
|
WO/2020/004014A1 |
The present invention provides: a culture medium and a culture medium additive which are for myogenic differentiation promotion and which contain ergothioneine, ascorbic acid 2-glucoside, ascorbic acid, or a combination thereof; a kit; a...
|
|
WO/2020/004568A1 |
The present invention provides a novel means for promoting equol production in human intestines or a novel means for amelioration of premenstrual syndrome, which is related to such equol production, and for improving skin condition chang...
|
|
WO/2020/004709A1 |
The present invention relates to a pharmaceutical composition comprising a combination of Erigeron annuus flower essential oil and botulinum toxin (Botox) for prevention or treatment of neuromuscular disease and a pharma-beauty compositi...
|
|
WO/2020/002715A1 |
The present invention relates to a pharmaceutical combination for use in the treatment, prevention and/or stabilization of age-related diseases and/or degenerative diseases. In particular, said pharmaceutical combination comprises a bigu...
|
|
WO/2019/246225A1 |
This disclosure provides methods of using compositions comprising amino acid entities to reduce fat infiltration in muscle, particularly under conditions of muscle atrophy. The disclosure also provides methods for enhancing muscle functi...
|
|
WO/2019/246125A1 |
Products and methods for treating dystroglycanopathies and laminin-deficient muscular dystrophies are provided. In the methods, a protein including a linker domain, such as the heparin-binding domain of Heparin-Binding Epidermal Growth F...
|
|
WO/2019/242687A1 |
The present invention discloses a 1,3-dioxane-4,6-dione compound, and a preparation method, a pharmaceutical composition, and an application thereof. The structure of the compound is represented by formula I, and the definition of each s...
|
|
WO/2019/241850A1 |
The present invention relates to substituted sulfonyl hydrazides that have the ability to inhibit lysine biosynthesis via the diaminopimelate pathway in certain organisms. As a result of this activity these compounds can be used in appli...
|
|
WO/2019/242039A1 |
Disclosed is a method for preparing a rocuronium bromide injection with a low impurity level, wherein the method makes use of the means of reducing the temperature of the formulation solution and nitrogen aeration, controlling the endoto...
|
|
WO/2019/241634A1 |
This document provides methods and materials involved in treating congenital disorders of glycosylation (CDGs). For example, methods for using a composition including one or more uridine diphosphate (UDP) - sugars to treat a mammal (e.g....
|
|
WO/2019/237185A1 |
The present disclosure relates to compounds comprising β-hydroxybutyric acid, and a weakly basic polymer. The disclosure also includes methods for inducing nutritional ketosis comprising administering the compounds or compositions compr...
|
|
WO/2019/241633A1 |
Disclosed herein are methods of treating or preventing a disease caused by nonsense mutations, or ameliorating one or more symptoms associated therewith, that involve administering to a patient in need thereof a therapeutically or prophy...
|
|
WO/2018/076060A9 |
Methods and compositions for producing mature myotubes are provided herein. In some instances, the method involves contacting a myoblast in an in vitro culture with a compound, wherein the contacting the myoblast in the in vitro culture ...
|
|
WO/2019/240126A1 |
[Problem] To provide a pharmaceutical composition that promotes the production of monoamine neurotransmitters in a living body having blood and cerebral fluid. [Solution] This pharmaceutical composition containing mesenchymal stem cells ...
|
|
WO/2019/234664A1 |
The present disclosure relates to a method of treating or preventing mitochondrial diseases by administering 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methy
l]-1,3-thiazolidine-2,4-dione or a salt thereof to a subject in nee...
|
|
WO/2019/235569A1 |
The present invention addresses the problem of providing: a novel kinase inhibitor and others; and a therapeutic agent for a disease, a drug discovery screening method and others, each utilizing the inhibitor and others. A compound repre...
|
|
WO/2019/236082A1 |
Provided herein are stem-cell based therapies for the treatment of neurodegenerative diseases and CNS disorder such as Huntington's disease. The therapy improved motor deficits and rescued synaptic alterations. The cells were shown to be...
|
|
WO/2019/235597A1 |
Provided is a compound which has little adverse side effects and a mild action and can be used for the activation of autophagy. An autophagy activating agent which contains S1PC or a salt thereof as an active ingredient.
|
